Record Information |
---|
Version | 2.0 |
---|
Creation Date | 2014-09-11 05:17:37 UTC |
---|
Update Date | 2014-12-24 20:26:57 UTC |
---|
Accession Number | T3D4811 |
---|
Identification |
---|
Common Name | Farnesol |
---|
Class | Small Molecule |
---|
Description | Farnesol is a signaling molecule that is derived from farnesyl diphosphate, an intermediate in the isoprenoid/cholesterol biosynthetic pathway. Farnesol is a 15 carbon isoprenoid alcohol is the corresponding dephosphorylated form of the isoprenoid farnesyl diphosphate. Farnesol has a potential role in controlling the degradation of 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase (EC 1.1.1.34, NADPH-hydroxymethylglutaryl-CoA reductase). The enzyme is stabilized under conditions of cellular sterol depletion (e.g. statin-treated cells) and rapidly degraded in sterol-loaded cells. In mammalian cells, this enhanced degradation is dependent on the presence of both a sterol and a non-sterol derived from the isoprenoid pathway; farnesol, the dephosphorylated form of farnesyl diphosphate, can function as the non-sterol component. Farnesol has been shown to activate the farnesoid receptor (FXR), a nuclear receptor that forms a functional heterodimer with RXR. Thus, dephosphorylation of farnesyl diphosphate, an intermediate in the cholesterol synthetic pathway, might produce an active ligand for the FXR:RXR heterodimer. The physiological ligand for FXR remains to be identified; farnesol, may simply mimic the unidentified natural ligand(s). In addition, exogenous farnesol have an effect on several other physiological processes, including inhibition of phosphatidylcholine biosynthesis, induction of apoptosis, inhibition of cell cycle progression and actin cytoskeletal disorganization. Farnesol cellular availability is an important determinant of vascular tone in animals and humans, and provides a basis for exploring farnesyl metabolism in humans with compromised vascular function as well as for using farnesyl analogues as regulators of arterial tone in vivo. A possible metabolic fate for farnesol is its conversion to farnesoic acid, and then to farnesol-derived dicarboxylic acids (FDDCAs) which would then be excreted in the urine. Farnesol can also be oxidized to a prenyl aldehyde, presumably by an alcohol dehydrogenase (ADH), and that this activity resides in the mitochondrial and peroxisomal. Liver Endoplasmic reticulum and peroxisomal fractions are able to phosphorylate farnesol to Farnesyl diphosphate in a Cytosine triphosphate dependent fashion. (1, 2, 3, 4). Prenol is polymerized by dehydration reactions; when there are at least four isoprene units (n in the above formula is greater than or equal to four), the polymer is called a polyprenol. Polyprenols can contain up to 100 isoprene units (n=100) linked end to end with the hydroxyl group (-OH) remaining at the end. These isoprenoid alcohols are also called terpenols These isoprenoid alcohols are important in the acylation of proteins, carotenoids, and fat-soluble vitamins A, E and K. They are also building blocks for plant oils such as farnesol and geraniol. Prenol is also a building block of cholesterol (built from six isoprene units), and thus of all steroids. Prenol has sedative properities, it is probably GABA receptor allosteric modulator.When the isoprene unit attached to the alcohol is saturated, the compound is referred to as a dolichol. Dolichols are important as glycosyl carriers in the synthesis of polysaccharides. |
---|
Compound Type | - Animal Toxin
- Cigarette Toxin
- Food Toxin
- Household Toxin
- Mammal Toxin
- Metabolite
- Natural Compound
- Organic Compound
|
---|
Chemical Structure | |
---|
Synonyms | Synonym | 2-cis,6-trans-Farnesol | 2-trans,6-trans-Farnesol | 3,7,11-Trimethyl-2,6,10-dodecatrien-1-ol | Farnesyl alcohol | FCI 119a | Nikkosome |
|
---|
Chemical Formula | C15H26O |
---|
Average Molecular Mass | 222.366 g/mol |
---|
Monoisotopic Mass | 222.198 g/mol |
---|
CAS Registry Number | 4602-84-0 |
---|
IUPAC Name | (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol |
---|
Traditional Name | (E)-farnesol |
---|
SMILES | [H]\C(CO)=C(\C)CC\C([H])=C(/C)CCC=C(C)C |
---|
InChI Identifier | InChI=1S/C15H26O/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-16/h7,9,11,16H,5-6,8,10,12H2,1-4H3/b14-9+,15-11+ |
---|
InChI Key | InChIKey=CRDAMVZIKSXKFV-YFVJMOTDSA-N |
---|
Chemical Taxonomy |
---|
Description | belongs to the class of organic compounds known as sesquiterpenoids. These are terpenes with three consecutive isoprene units. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Prenol lipids |
---|
Sub Class | Sesquiterpenoids |
---|
Direct Parent | Sesquiterpenoids |
---|
Alternative Parents | |
---|
Substituents | - Farsesane sesquiterpenoid
- Sesquiterpenoid
- Fatty alcohol
- Fatty acyl
- Organic oxygen compound
- Hydrocarbon derivative
- Primary alcohol
- Organooxygen compound
- Alcohol
- Aliphatic acyclic compound
|
---|
Molecular Framework | Aliphatic acyclic compounds |
---|
External Descriptors | |
---|
Biological Properties |
---|
Status | Detected and Not Quantified |
---|
Origin | Endogenous |
---|
Cellular Locations | |
---|
Biofluid Locations | Not Available |
---|
Tissue Locations | - Epidermis
- Fibroblasts
- Intestine
- Kidney
|
---|
Pathways | Not Available |
---|
Applications | Not Available |
---|
Biological Roles | Not Available |
---|
Chemical Roles | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Appearance | White powder. |
---|
Experimental Properties | Property | Value |
---|
Melting Point | < 25°C | Boiling Point | 111°C at 3.50E-01 mm Hg | Solubility | Not Available | LogP | Not Available |
|
---|
Predicted Properties | |
---|
Spectra |
---|
Spectra | Spectrum Type | Description | Splash Key | Deposition Date | View |
---|
GC-MS | GC-MS Spectrum - GC-MS (1 TMS) | splash10-000x-9800000000-0366097ae9a2af6bafce | 2014-06-16 | View Spectrum | GC-MS | GC-MS Spectrum - GC-MS (1 TMS) | splash10-001l-9800000000-eec57a93bb5862e554f1 | 2014-06-16 | View Spectrum | GC-MS | GC-MS Spectrum - GC-MS (1 TMS) | splash10-000x-8900000000-9c20df8f2d1959c137d7 | 2014-06-16 | View Spectrum | GC-MS | GC-MS Spectrum - GC-MS (Non-derivatized) | splash10-000x-9800000000-0366097ae9a2af6bafce | 2017-09-12 | View Spectrum | GC-MS | GC-MS Spectrum - GC-MS (Non-derivatized) | splash10-001l-9800000000-eec57a93bb5862e554f1 | 2017-09-12 | View Spectrum | GC-MS | GC-MS Spectrum - GC-MS (Non-derivatized) | splash10-000x-8900000000-9c20df8f2d1959c137d7 | 2017-09-12 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | splash10-0a4u-9830000000-5e08d59a4cc2e87c9984 | 2016-09-22 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (1 TMS) - 70eV, Positive | splash10-05xr-9860000000-2eeca721058a47519afd | 2017-10-06 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - Linear Ion Trap , positive | splash10-003u-0790000000-578343425424f42c9d58 | 2017-09-14 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-0ab9-1590000000-88a1356fe7cab3171954 | 2016-06-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-0avi-7930000000-81c18181dbd66735216a | 2016-06-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-0gi0-9400000000-e44ecbea8a96f84abd43 | 2016-06-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-00di-0390000000-9beef594142e0da5de92 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-006x-1980000000-3b9708ac6185abaf6d96 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-05bf-4910000000-a8db2089f5647c8532ad | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-00di-0090000000-ab61d8a2af41e6ed2e49 | 2021-09-22 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-00di-0690000000-8a43271c10743cad1e3e | 2021-09-22 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-00l2-4900000000-7dcaa3b1e66cfbe960c9 | 2021-09-22 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-05gi-5930000000-9f54facb49232e1c6a46 | 2021-09-22 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-05o0-9600000000-55d109ed92e3da30c7ea | 2021-09-22 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-00l6-9100000000-bcc664ee21d185da076e | 2021-09-22 | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-014l-9200000000-8e5fae6943a545e4bc0b | 2014-09-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 100 MHz, H2O, predicted) | Not Available | 2022-08-23 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 100 MHz, H2O, predicted) | Not Available | 2022-08-23 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, H2O, predicted) | Not Available | 2022-08-23 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, H2O, predicted) | Not Available | 2022-08-23 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 200 MHz, H2O, predicted) | Not Available | 2022-08-23 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 200 MHz, H2O, predicted) | Not Available | 2022-08-23 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 300 MHz, H2O, predicted) | Not Available | 2022-08-23 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 300 MHz, H2O, predicted) | Not Available | 2022-08-23 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 400 MHz, H2O, predicted) | Not Available | 2022-08-23 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, H2O, predicted) | Not Available | 2022-08-23 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 500 MHz, H2O, predicted) | Not Available | 2022-08-23 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, H2O, predicted) | Not Available | 2022-08-23 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 600 MHz, H2O, predicted) | Not Available | 2022-08-23 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, H2O, predicted) | Not Available | 2022-08-23 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 700 MHz, H2O, predicted) | Not Available | 2022-08-23 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 700 MHz, H2O, predicted) | Not Available | 2022-08-23 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 800 MHz, H2O, predicted) | Not Available | 2022-08-23 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 800 MHz, H2O, predicted) | Not Available | 2022-08-23 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 900 MHz, H2O, predicted) | Not Available | 2022-08-23 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 900 MHz, H2O, predicted) | Not Available | 2022-08-23 | View Spectrum |
|
---|
Toxicity Profile |
---|
Route of Exposure | Not Available |
---|
Mechanism of Toxicity | Not Available |
---|
Metabolism | Not Available |
---|
Toxicity Values | Not Available |
---|
Lethal Dose | Not Available |
---|
Carcinogenicity (IARC Classification) | No indication of carcinogenicity to humans (not listed by IARC). |
---|
Uses/Sources | This is an endogenously produced metabolite found in the human body. It is used in metabolic reactions, catabolic reactions or waste generation. |
---|
Minimum Risk Level | Not Available |
---|
Health Effects | Not Available |
---|
Symptoms | Not Available |
---|
Treatment | Not Available |
---|
Normal Concentrations |
---|
| Not Available |
---|
Abnormal Concentrations |
---|
| Not Available |
---|
External Links |
---|
DrugBank ID | DB02509 |
---|
HMDB ID | HMDB04305 |
---|
PubChem Compound ID | 1549107 |
---|
ChEMBL ID | Not Available |
---|
ChemSpider ID | 1266073 |
---|
KEGG ID | C01493 |
---|
UniProt ID | Not Available |
---|
OMIM ID | |
---|
ChEBI ID | 28600 |
---|
BioCyc ID | 2-TRANS6-TRANS-FARNESOL |
---|
CTD ID | D005204 |
---|
Stitch ID | Not Available |
---|
PDB ID | Not Available |
---|
ACToR ID | Not Available |
---|
Wikipedia Link | Farnesol |
---|
References |
---|
Synthesis Reference | James Millis, “Production of farnesol and geranylgeraniol.” U.S. Patent US20030092144, issued May 15, 2003. |
---|
MSDS | Link |
---|
General References | - Edwards PA, Ericsson J: Signaling molecules derived from the cholesterol biosynthetic pathway: mechanisms of action and possible roles in human disease. Curr Opin Lipidol. 1998 Oct;9(5):433-40. [9812197 ]
- Roullet JB, Xue H, Chapman J, McDougal P, Roullet CM, McCarron DA: Farnesyl analogues inhibit vasoconstriction in animal and human arteries. J Clin Invest. 1996 May 15;97(10):2384-90. [8636420 ]
- Bostedor RG, Karkas JD, Arison BH, Bansal VS, Vaidya S, Germershausen JI, Kurtz MM, Bergstrom JD: Farnesol-derived dicarboxylic acids in the urine of animals treated with zaragozic acid A or with farnesol. J Biol Chem. 1997 Apr 4;272(14):9197-203. [9083051 ]
- Westfall D, Aboushadi N, Shackelford JE, Krisans SK: Metabolism of farnesol: phosphorylation of farnesol by rat liver microsomal and peroxisomal fractions. Biochem Biophys Res Commun. 1997 Jan 23;230(3):562-8. [9015362 ]
- Horn TL, Long L, Cwik MJ, Morrissey RL, Kapetanovic IM, McCormick DL: Modulation of hepatic and renal drug metabolizing enzyme activities in rats by subchronic administration of farnesol. Chem Biol Interact. 2005 Apr 15;152(2-3):79-99. [15840382 ]
- Hanley K, Wood L, Ng DC, He SS, Lau P, Moser A, Elias PM, Bikle DD, Williams ML, Feingold KR: Cholesterol sulfate stimulates involucrin transcription in keratinocytes by increasing Fra-1, Fra-2, and Jun D. J Lipid Res. 2001 Mar;42(3):390-8. [11254751 ]
- DeBarber AE, Bleyle LA, Roullet JB, Koop DR: Omega-hydroxylation of farnesol by mammalian cytochromes p450. Biochim Biophys Acta. 2004 Jun 1;1682(1-3):18-27. [15158752 ]
- Saidi S, Luitaud C, Rouabhia M: In vitro synergistic effect of farnesol and human gingival cells against Candida albicans. Yeast. 2006 Jul 15;23(9):673-87. [16845684 ]
- Hanley K, Komuves LG, Ng DC, Schoonjans K, He SS, Lau P, Bikle DD, Williams ML, Elias PM, Auwerx J, Feingold KR: Farnesol stimulates differentiation in epidermal keratinocytes via PPARalpha. J Biol Chem. 2000 Apr 14;275(15):11484-91. [10753967 ]
- Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, Noonan DJ, Burka LT, McMorris T, Lamph WW, Evans RM, Weinberger C: Identification of a nuclear receptor that is activated by farnesol metabolites. Cell. 1995 Jun 2;81(5):687-93. [7774010 ]
- Staines AG, Sindelar P, Coughtrie MW, Burchell B: Farnesol is glucuronidated in human liver, kidney and intestine in vitro, and is a novel substrate for UGT2B7 and UGT1A1. Biochem J. 2004 Dec 15;384(Pt 3):637-45. [15320866 ]
- Fayard E, Schoonjans K, Auwerx J: Xol INXS: role of the liver X and the farnesol X receptors. Curr Opin Lipidol. 2001 Apr;12(2):113-20. [11264982 ]
|
---|
Gene Regulation |
---|
Up-Regulated Genes | Not Available |
---|
Down-Regulated Genes | Not Available |
---|